104 related articles for article (PubMed ID: 22027480)
1. Prothrombin index slope is an early prognostic marker in patients with severe acute liver diseases.
Nalpas B; Francoz C; Ichaï P; Jamot L; Faivre J; Lemoinne S; Samuel D; Durand F; Bernuau J; Bréchot C; Amouyal P; Amouyal G
Gut; 2012 Jul; 61(7):1098-100. PubMed ID: 22027480
[No Abstract] [Full Text] [Related]
2. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of von willebrand factor in cirrhosis: a possible mechanism.
Eapen CE; Elias JE; Mackie I; Elias E
Hepatology; 2013 Sep; 58(3):1189. PubMed ID: 23348722
[No Abstract] [Full Text] [Related]
4. Reply: To PMID 22532296.
Ferlitsch M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2013 Sep; 58(3):1189-90. PubMed ID: 23359328
[No Abstract] [Full Text] [Related]
5. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
6. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis.
Langholm LL; Manon-Jensen T; Karsdal MA; Bendtsen F; Leeming DJ; Møller S
Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1040-1048. PubMed ID: 30768435
[TBL] [Abstract][Full Text] [Related]
7. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
[TBL] [Abstract][Full Text] [Related]
8. Systemic clotting activation by low-grade endotoxaemia in liver cirrhosis: a potential role for endothelial procoagulant activation.
Ferro D; Basili S; Lattuada A; Mantovani B; Bellomo A; Mannucci PM; Violi F
Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):434-40. PubMed ID: 9494853
[TBL] [Abstract][Full Text] [Related]
9. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.
Wu H; Yan S; Wang G; Cui S; Zhang C; Zhu Q
Scand J Gastroenterol; 2015; 50(9):1160-9. PubMed ID: 25877661
[TBL] [Abstract][Full Text] [Related]
10. Normal fibronectin levels after surgical treatment of portal hypertension in liver cirrhosis.
De Angelis V; Zambon M; Toffolo L; Voltan GP; Orazi BM; Santarossa L; Donada C; Zuin R
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(1):89-93. PubMed ID: 1695189
[TBL] [Abstract][Full Text] [Related]
11. [Effects of changes in central hemodynamics and hormonal systems of its regulation on the etiology of portal hypertension complications in patients with liver cirrhosis].
Tsykin DB; Iampol'skaia LI; Borisov AE; Tsykina GA; Shcherba IuV; Oktiabr'skaia IN; Levina AE
Klin Med (Mosk); 1995; 73(4):99. PubMed ID: 7474848
[No Abstract] [Full Text] [Related]
12. von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis.
Kalambokis GN; Baltayiannis G; Christodoulou D
World J Gastroenterol; 2016 May; 22(19):4786-8. PubMed ID: 27217711
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.
Bruha R; Jachymova M; Petrtyl J; Dvorak K; Lenicek M; Urbanek P; Svestka T; Vitek L
World J Gastroenterol; 2016 Mar; 22(12):3441-50. PubMed ID: 27022226
[TBL] [Abstract][Full Text] [Related]
14. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
[TBL] [Abstract][Full Text] [Related]
15. [Circulation in liver cirrhosis patients and the principles for correcting portal hypertension].
Patsiora MD; Ershov IuA
Khirurgiia (Mosk); 1973 May; 49(5):72-9. PubMed ID: 4795477
[No Abstract] [Full Text] [Related]
16. Estrogens and portal hypertension in cirrhosis of the liver.
Gluud C; Henriksen HH; Svenstrup B
N Engl J Med; 1981 Jan; 304(1):52. PubMed ID: 7432439
[No Abstract] [Full Text] [Related]
17. Plasma angiotensin activity in cirrhosis of the liver and idiopathic portal hypertension.
Dass BK; Chaudhury RR; Chhuttani PN; Saini VK; Datta DV
Indian J Med Res; 1976 Mar; 64(3):418-24. PubMed ID: 965044
[No Abstract] [Full Text] [Related]
18. [Serum haptoglobins in hepatic cirrhosis with portal hypertension and secondary hypersplenism].
Vai C; Santese R; Andreuzzi B; Gelosa F; Rotondo F
Minerva Dietol Gastroenterol; 1983; 29(4):313-6. PubMed ID: 6672672
[No Abstract] [Full Text] [Related]
19. Interrelationship between insulin resistance and portal haemodynamic abnormality in cirrhosis.
Maruyama H; Kobayashi K; Kiyono S; Yokosuka O
Int J Med Sci; 2017; 14(3):240-245. PubMed ID: 28367084
[No Abstract] [Full Text] [Related]
20. [Pathogenesis of the cytopenia syndrome in patients with cirrhosis of the liver complicated by portal hypertension].
Eramishantsev AK; Korshunov IB; Belokrinitskiĭ DV; Dudkina LN; Dem'ianov AI
Khirurgiia (Mosk); 1989 Feb; (2):36-9. PubMed ID: 2709711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
